Eosinophilic Myocarditis in a Patient With Multiple Myeloma.

[1]  L. Potena,et al.  Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. , 2019, Journal of the American College of Cardiology.

[2]  T. Dardas,et al.  FROM MULTIPLE MYELOMA TO MYOCARDITIS , 2019, Journal of the American College of Cardiology.

[3]  Uzair Yaqoob,et al.  The Clinicopathological Profile of Eosinophilic Myocarditis , 2018, Cureus.

[4]  Jaeho Bae,et al.  The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells , 2018, Journal of radiation research.

[5]  K. Klingel,et al.  Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. , 2017, Journal of the American College of Cardiology.

[6]  S. Phillips,et al.  Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma , 2017, Cardio-Oncology.

[7]  E. Hatzimichael,et al.  “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group , 2013, Annals of Hematology.

[8]  M. Krause,et al.  Radiotherapy and "new" drugs-new side effects? , 2011, Radiation oncology.

[9]  J. Carver,et al.  Myocarditis During Lenalidomide Therapy , 2010, The Annals of pharmacotherapy.

[10]  P. Wen,et al.  A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. , 2009, International journal of radiation oncology, biology, physics.

[11]  F. Meyer,et al.  Dysregulation of the Ubiquitin-Proteasome System in Human Carotid Atherosclerosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.